IMPACT OF COVID-19 ON TUBERCULOSIS CASE DETECTION IN VIET NAM: A MODELLING ANALYSIS

Viet Long Bui[1,*], Romain Ragonnet[1], Angus E. Hughes[1], David S. Shipman[1], Emma S. McBryde[2], Binh Hoa Nguyen [3,4], Hoang Nam Do[3,4], Thai Son Ha[5], Greg J. Fox[6,7], James M. Trauer[1]

[1] School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

[2] Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia

[3] National Lung Hospital, Ha Noi, Viet Nam

[4] National Tuberculosis Program, Ha Noi, Viet Nam

[5] Administration of Medical Services, Ministry of Health, Ha Noi, Viet Nam

[6] Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

[7] The Woolcock Institute for Medical Research, Glebe, New South Wales, Australia

* Corresponding author, email viet.bui1@monash.edu

ABSTRACT

Background

Viet Nam, a high-burden tuberculosis (TB) country, observed marked declines in TB notifications during the COVID-19 pandemic. We sought to determine whether and how COVID-19-related factors have influenced TB transmission and control, as well as their long-term effects, aiming to inform and enhance TB control strategies.

Methods

We developed a compartmental TB transmission model to estimate COVID-19's impact on TB detection and transmission in Vietnam. We simulated future scenarios to evaluate the potential benefits of enhanced TB case detection.

Results

The COVID-19 pandemic significantly impacted TB control in Viet Nam, leading to a sharp decline in case detection in 2021. This resulted in approximately 1,900 new TB episodes (95% credible interval [CrI]: 200 - 5,100) and 1,100 TB-related deaths (95% CrI: 100 - 2,700) in that year. Projections suggest that by 2035, these disruptions could contribute to 22,000 additional TB episodes (95% CrI: 1,900 - 63,000) and 5,900 more deaths (95% CrI: 600 - 16,600). We predicted two hypothetical scenarios of enhancing TB case detection. Under the ambitious scenario, enhancing TB case detection could mitigate these potential impacts by preventing 17.8% of new TB episodes (95%CrI: 13.1% - 21.9%) and 34.2% (95%CrI: 31.5% - 37.0%) of TB-related deaths by 2035, compared to no enhancement.

Conclusions

COVID-19 disruptions have created a backlog of undiagnosed TB cases, increasing transmission and mortality. Sustained investment in diagnostics, healthcare resilience, and proactive policies is essential to mitigate long-term consequences.

Keywords: Mycobacterium tuberculosis, COVID-19 pandemic, Case detection, Transmission dynamic model, compartmental model.

INTRODUCTION

Tuberculosis (TB), the disease caused by the bacterium *Mycobacterium tuberculosis (M.tb)*, remains a critical global public health challenge. Despite considerable progress in recent decades, TB continues to be one of the top infectious disease killers worldwide [1]. Viet Nam, as a high-burden country, exemplifies the difficulties in controlling TB. Its continuing high burden highlights the urgent need for improved public health strategies, and understanding its epidemic drivers may offer valuable insights for addressing TB in similar settings globally [1].

The COVID-19 pandemic severely disrupted global TB control, causing significant declines in TB notifications in high-burden countries like India, South Africa, Brazil, and Indonesia [2–4]. An interrupted time-series analysis estimated an 8% decrease in TB notifications in Viet Nam attributable to pandemic effects [5]. The World Health Organization (WHO) reported an 18% global decline in TB notifications in 2020, with an estimated 200,000–400,000 additional TB deaths [2, 6]. However, WHO's assessments rely on national TB program reports [7], which may underestimate the true burden due to undiagnosed cases and limited surveillance capacity. Initial projections were based on notification trends rather than dynamic transmission models, which may not be the optimal approach to predicting long-term TB impact estimates. The reduction in TB notifications may be attributable to healthcare disruptions, resource diversion, reduced healthcare-seeking behavior or some combination of these factors. However, COVID-19 measures like mask-wearing and social distancing may have reduced TB transmission, which are not accounted for in WHO's early estimates [6].

To address these challenges, we developed a deterministic compartmental model to simulate the transmission dynamics of *M.tb* in Viet Nam. Through this model, we aimed to quantify the long-term impacts of COVID-19 on TB control over the next decade.

METHODS:

1. Model structure

We developed a deterministic compartmental model comprising six compartment types - Susceptible (S), Early latent (E), Late latent (L), Active TB or infectious (I), Treatment (T), and recovered (R) - to represent different TB-related infection and disease states, using a similar conceptual approach and assumptions as our previously published model [8]. A detailed description of the model structure and all associated methods are provided in the Supplemental Material.



Figure 1. Model structure. *Boxes represent different compartment types: Susceptible (S), Early latent infection (E), Late latent (L), Active TB (I), Treatment (T) and Recovered (R). Subscripts indicate stratification by age (a) and pulmonary/smear status (f).*

We stratified these base compartments into six age groups (0–4, 5–14, 15–34, 35–49, 50–69, and 70+ years) to capture demographic processes of birth, aging, and death, as well as age-specific contact patterns informed by a contact survey performed in Viet Nam [9]. Model compartments were further stratified by pulmonary/smear status into smear-positive, smear-negative and extrapulmonary forms of TB (SPTB, SNTB and EPTB) to account for differences in infectiousness, detection, and fatality risks.

The reduction in TB notifications during the COVID-19 pandemic could plausibly be attributable to reduced case detection, decreased transmission, or both. To model these effects, we considered four candidate assumptions: Assumption 1, the COVID-19 pandemic had no impact on either TB case detection or transmission; Assumption 2, only case detection was reduced, reflecting the

decline in healthcare access, while TB transmission remained unaffected; Assumption 3, only TB transmission was reduced, with PHSMs limiting transmission, but case detection continued unaffected; Assumption 4, both case detection and TB transmission were reduced, incorporating the effects of both PHSMs and healthcare disruptions.

2. Parameterization and calibration

Table S6 (Supplementary Material) presents all model parameters. Table S7 (Supplementary Material) specifies the prior distributions for the model parameters that were varied through our calibration algorithm, including contact rate, natural history-related, and latency-related parameters.

One of the key parameters in our model was rate of commencing treatment of active TB, the rate at which individuals with active TB (I) transition to the treatment compartment (T). This rate is the reciprocal of the average time from developing active TB to first presentation and treatment initiation under the NTP and the diagnostic algorithm's sensitivity, accounting for the relative difficulty diagnosing SNTB and EPTB compared to SPTB. The average time from developing active TB to first presentation and treatment initiation reflects the delays attributable to the patient, provider, and health system factors, which can lead to delayed diagnoses. We used a smooth transition function that gradually increased with the historical improvements in the availability of TB diagnostics and treatments. More details are provided in the Supplementary Material.

In our model, the impacts of COVID-19 on TB transmission and case detection were incorporated through the use of reduction factors with minimally informative priors from 0.01 to 0.9. Specifically, under Assumptions 2 and 4, these reduction factors are applied to the rate of treatment commencement, while under Assumptions 3 and 4, they are applied to the contact rate. These factors were varied under the calibration process to capture the possible impact.

We calibrated our model to align with local data, including total national population size (2019 Vietnam Population and Housing Census [10]), TB notifications (reported to WHO [11]), and the

prevalence of bacteriologically-confirmed and of smear-positive pulmonary TB among adults (the second national TB prevalence survey [12]) (Table S8, Supplementary Materials). The calibration process involved Latin hypercube sampling followed by optimization for initialization, followed by Bayesian sampling for the warm-up and main phases of calibration. Last, we randomly select 1,000 accepted runs of the main calibration phase to generate uncertainty ranges. The best assumption regarding COVID-19 impacts on TB dynamics was identified by comparing the expected log pointwise predictive density Watanabe-Akaike Information Criterion (EPLD-WAIC) values across four scenarios, with less negative values indicating better predictive performance [13].

3. Future projections

Using the best candidate assumption, we evaluated the impact of the COVID-19 pandemic on TB control by projecting the number of new TB cases and TB-related deaths from 2025 to 2035. By comparing the status quo scenario -representing the current trajectory of TB control, including disruptions caused by the pandemic -with a counterfactual scenario where COVID-19 had no impact on TB detection, we quantified the pandemic's effects on TB control efforts and assessed its long-term consequences. For comparison, we evaluated the potential impact of future interventions to enhance case detection activities between 2025 and 2035. We considered a 2-fold and 5-fold increase in the rate of commencing treatment by 2035. For each scenario, we estimated the total number of new TB episodes and TB-related deaths averted.

4. Software

We used *summer*, a Python-based epidemiological modelling framework [14], and the *estival* package for facilitating optimization and calibration, along with the external libraries *nevergrad* [15] and the DEMetropolisZ [16] algorithm from *PyMC.* Our model development, optimization, and calibration followed a pipeline equivalent to that detailed in [17]. The code used for the analyses are accessible in a GitHub repository at: https://github.com/vlbui/tbdynamics.

RESULTS

1. Calibration results

Candidate model comparison



Figure 2. **Model fits to the historical profile of case notifications under our four candidate assumptions regarding the effect of COVID-19 on *M.tb* dynamics.** *Solid lines represent median model estimates. Shaded areas show corresponding interquartile ranges (dark shade) and 95% credible intervals (light shade).* ***Assumption 1:*** *The COVID-19 pandemic had no impact on TB case detection or transmission.* ***Assumption 2:*** *Only case detection was reduced.* ***Assumption 3:*** *Only TB transmission was reduced.* ***Assumption 4:*** *Both case detection and TB transmission were reduced, incorporating effects from both social distancing and healthcare disruption.*

All four assumptions closely matched the total population size and the prevalence of TB among adults, as shown in Figures S3 and S4. However, the fit varied when comparing the actual number of TB case notifications to the equivalent model output. Figure 2 shows this comparison under our four candidate assumptions regarding the effect of COVID-19 on *M.tb* dynamics. Among the assumptions, Assumption 2 (COVID-19 only affected TB case detection) provided the best fit to the observed sharp decline in TB notifications in 2021, slightly outperforming Assumption 4 (COVID-19 reduced both case detection and transmission) based on our assessment with the EPLD-WAIC (see Table S6). In contrast, Assumptions 1 (no impact of COVID-19) and 3 (COVID-19 only reduced transmission) showed a poorer fit to the data.

Based on this preceding analysis, we selected Assumption 2 as our primary model for the following in-depth examination of *M.tb* dynamics in Viet Nam. Figure 3 illustrates the comparison between accepted model runs, each calibration target, and other epidemiological estimates not included in our calibration algorithm that we considered for model validation. Figure S5 presents model outputs for calibration targets and other estimates derived from the 50 randomly accepted model runs.

Table S7 (Supplementary Material) details the posterior estimates and calibration metrics for the calibrated parameters of our preferred candidate model. The algorithm demonstrated highly satisfactory chain convergence, as evidenced by each parameter's Gelman-Rubin statistic ($\hat{R}$) being below 1.05 and all effective sample sizes exceeding 150. Figure S6 shows the trace plots for each parameter, illustrating their convergence and stability throughout the execution of the calibration algorithm. Figure S7 (Supplementary Material) overlays posterior distributions on the corresponding priors of the calibrated parameters. The posterior estimate for the reduction of COVID-19 on case detection was 0.33 with 94% high density interval ranging from 0.01 to 0.677. Figure S8 (Supplementary Material) shows how the posterior distributions for the natural history parameters translate into the more epidemiologically intuitive quantities of disease duration and case fatality rate for SPTB and SNTB.

Given the lack of historical data, the first 200 years of the simulation exhibited significant uncertainty, which progressively diminished in later years (Figure S10). Our calibration algorithm simulated a peak in adult pulmonary TB prevalence that began to decline from around 1986, coinciding with the establishment of the NTP. By 2017, the model predicted an adult pulmonary TB prevalence of 328 cases per 100,000 populations (95% CrI: 269–399), closely matching our prevalence survey target, which estimated bacteriologically-confirmed TB among adults at 322 (confidence interval – CI: 260–399) per 100,000 in 2017 [12].

We estimated TB incidence in 2022 at 153 cases per 100,000 population (95% CrI: 117 - 202), which closely matches the WHO's 2022 estimate of 176 cases per 100,000 (95% CI: 121 - 251) [11]. We estimated that approximately 18,000 people have died from TB each year since 2010, or about 18 deaths per 100,000 population. Our modelled prevalence of adult SPTB aligned closely with the results of the 2007 national prevalence survey (95 per 100,000, 95% CrI: 72 - 127, compared to 99 per 100,000, 95% CI: 78 - 125) [18], but was somewhat higher than the 2017 survey results (73 cases per 100,000, 95% CrI: 59 - 88, compared to 46 cases per 100,000, 95% CI: 32 - 68) [12]. Figure S9 (Supplementary Material) illustrates the proportion of active TB cases originating from the early latent phase, highlighting that 50% or more of these cases were due to early progression and therefore recent transmission throughout most of the recent simulation period. A minor increase in the proportional contribution of recent transmission was observed in 2021 during the COVID-19 pandemic. The modelled prevalence of LTBI in 2019 was 45% of the total population (95%CrI: 39% - 51%). This aligns closely with the estimate from Ding et al. [19], which places the LTBI prevalence at around 44% of the population, also within our CrI. Figure S109 (Supplementary Material) shows the proportions of the population by compartment based on results from the maximum likelihood run.



Figure 3. Comparison between outputs and empiric observation targets other than annual case notifications for Viet Nam, under the best-fitting candidate model configuration (Assumption 2). *Model predictions are represented as median (solid line), interquartile credible interval (dark blue shade) and 95% central credible interval (light blue shade). Red points and vertical line (where available) show the point estimates and confidence interval for each calibration target, while purple points indicate estimates from literature that are presented for comparison but were not used as calibration targets. Legends indicate the data source for each target.*

Figure S11 (Supplementary Material) shows the estimated increasing profile of the rate of commencing treatment over time, with the increase beginning from around 1986, which coincides with the establishment of the Viet Nam NTP [20]. The modelled rate shows a steep inflection, accelerating most rapidly through the late 1990s, six years after the implementation of the DOTS strategy [20]. The median case detection proportion stabilized at around 0.6 from 2010 onwards, which can be interpreted as meaning that about 60% of incident cases were successfully detected and commenced treatment. Specifically, we estimated a 33% reduction in the rate of commencing treatment, during COVID-19, resulting in a 0.43-year (equivalent to 23 weeks) increase in the time to active TB onset to detection and treatment.

2. Future projection

Long-term impacts of COVID-19 on TB incidence and TB deaths

Figure 4 illustrates how the COVID-19-related health system effects may contribute to impeding future TB control efforts under Assumption 2, in comparison with a counterfactual scenario that COVID-19 had no effect on TB notifications. In 2021, we estimated 1,900 additional TB episodes (95% CrI: 200 – 5,100) and 1100 additional TB deaths associated with the effects of COVID-19 (95% CrI: 100 – 2,700). By 2035, the cumulative annual burden could rise 22,000 more TB episodes (95% CrI: 1,900 – 63,000) and 5,900 more deaths (95% CrI: 600 – 16,600).



Figure 4. Impact of the COVID-19 pandemic on the cumulative number of TB epidodes and TB-related deaths from 2021 to 2035 compared to a counterfactual scenario that COVID-19 had no effect on TB notifications. *Values are presented on a logarithmic scale. Projections made under Assumption 2, COVID-19 only affects case detection.* *Cumulative diseased: cumulative new TB cases, Cumulative deaths: cumulative number of deaths due to TB. Lines indicate the 95% credible intervals of the estimates.*

In 2024, we estimated the average delay to diagnosing and treating an active TB case at 1.80 years, such that our scenarios are equivalent to reducing the delay time to 0.9 years (approximately 47 weeks) with a 2-fold increase, and to 0.36 years (approximately 19 weeks) with 5-fold in rate of commencing care. Our projections of the results of these scenarios are presented in Figure 5. Compared to a *'status quo'* projection, enhanced case detection by increasing the rate of commencing care 5-fold may prevent approximately 433,500 (95%CrI: 249,400 – 692,200) new TB episodes, representing a 17.8% reduction (95%CrI: 13.1% - 21.9%). Additionally, this scenario may avert 109,900 (95%CrI: 68,500 – 169,900) TB-related deaths, equivalent to 34.2% (95%CrI: 31.5% - 37.0%) of all TB-related dêaths over the coming decade. Notably, enhancing TB case detection may have an even greater impact on reducing TB-related mortality.



Figure 5. Number of cumulative new TB episodes and TB-related deaths averted under two scenarios of enhancing case detection comparing to *'status quo scenario'*. Values are presented on a logarithmic scale. *The 'status quo' scenario assumes case detection remains unchanged. Scenario 1 models a 2-fold increase and Scenario 2 models a 5-fold increase in the rate at which persons with active TB commence care. Lines indicate the 95% credible intervals of the estimates.*

DISCUSSION

Our results show that the decline in TB detection during COVID-19 was primarily responsible for the sharp drop in TB notifications in Viet Nam in 2021. This disruption has likely contributed to a backlog of undiagnosed cases, sustaining TB transmission and potentially leading to long-term increases in incidence and mortality. Our methodological approach, developed using open-source packages, supports data input manipulation, compartmental model construction, execution, and calibration, providing a flexible and efficient tool for developing, optimizing, and calibrating complex epidemiological models while promoting reproducibility and adaptability. [17].

he close alignment between the model-simulated indicators, including the population size, TB notifications and pulmonary TB prevalence demonstrates our model's capacity to capture multiple key observations reflecting TB burden. We found that COVID-19 was associated with significant reductions in TB case detection, which poses a serious threat to long-term TB control efforts, which aligns with findings of other studies [20, 21]. However, Viet Nam has gained lessons from the

COVID-19 pandemic to enhance TB case detection, focusing on decentralized services and proactive case-finding efforts. The "Double X" (2X) strategy, which utilizes chest radiography and GeneXpert rapid diagnostic testing, has improved early TB detection, particularly in vulnerable populations [5, 22, 23]. Continuing and expanding these programs may further strengthen TB surveillance, improve case detection rates, and mitigate long-term disruptions to TB control efforts.

The model configuration incorporating both reduced case detection and transmission reduction performed almost as well as that with reduced case detection only. However, the configuration that incorporated a reduction in case detection aligned most closely with observed trends, showing how COVID-19-related healthcare disruptions likely delayed diagnosis and treatment, leading to fewer reported cases. The detection process is obviously crucial for timely treatment commencement, and any disruption creates a backlog of undiagnosed cases, sustaining transmission within communities. Under the assumption that COVID-19 reduced case detection, our model found a small increase in the relative importance of recent transmission to driving the epidemic during this period. Over time, this accumulated backlog continues to exacerbate transmission as more cases remain undetected. Thus, while we cannot exclude that contact reduction due to COVID-19 measures like social distancing and lockdowns had a small impact on transmission, the steep decline in case detection likely played the predominant role in influencing TB notification numbers during the pandemic period. The wide credible intervals for the additional future TB cases and deaths likely reflect the uncertainty in estimating the impact of COVID-19, the compounding effects of increased transmission over time and the general uncertainty associated with our long-term projections Nevertheless, the possibility of a major adverse effect on the epidemic emphasizes the importance of restoring and strengthening TB case detection efforts to mitigate the pandemic's lasting impact on TB control. This proactive approach not only manages the immediate effects of disruptions like those experienced during COVID-19 but also reduces long-term disease burden, saving more lives by ensuring that fewer cases go unnoticed and untreated. However, achieving this requires substantial efforts, increased investment, and strong commitment. Any major disruption now or into

the future - whether due to another pandemic, other public health crises - could further exacerbate TB control challenges.

The calibration of four candidate models yielded similar parameter inferences, demonstrating that the sharp reduction in notifications during the COVID-19 period provides information to quantify the pandemic effect, although non-COVID-19-related parameter estimates were not significantly constrained. That is, while the profile of COVID-19-related changes to notification rates over time provides information to understand the effect of COVID-19 itself, it does not enhance our ability to refine more general TB-related epidemiological parameter values (e.g. those relating to the natural history of infection and disease).

The modelled delay from active TB to diagnosis and treatment can be interpreted as being exponentially distributed with an average time to diagnosis of approximately 1.80 years, implying that many cases remain undetected. Superficially, this delay may appear higher than prior studies. For example, one review found that, in low- and lower-middle-income countries, median delays were 28 days for patient-related delays, 14 days for health system-related delays, and 14 days for treatment commencement-related delays, compared to 10, 4, and 0 days in upper-middle-income countries [24]. In high-endemic areas, total diagnostic delays often exceeded 120 days, typically ranging from 60 to 90 days, influenced by gender, rural residence, and health system inefficiencies [24, 25]. Variation in the definition of first healthcare-seeking behavior further complicates comparisons, with definitions ranging from visits to qualified providers to any contact with the NTP [24]. Additionally, asymptomatic TB constitutes a substantial proportion of cases, with 27.7–82.7% depending on symptom criteria [26], and 36.1–79.7% (median 50.4%) in high-prevalence settings [27]. Similar prevalence is reported in subgroups like children and people with diabetes [28].

Our study has limitations stemming from uncertainties in TB epidemiology and natural history. While recent research provides estimates for progression rates from LTBI to active TB, LTBI reactivation remains difficult to observe [29, 30], and we relied on several estimates from low-burden settings or

from pre-chemotherapy era, that may not be fully applicable to the context of Viet Nam. The difficulty in conducting longitudinal studies in high-burden areas further complicates the precision of these estimates, potentially affecting the generalizability of our findings [31]. Despite this, these estimates aligned well with observed data, offering a more accurate foundation than broad assumptions like a 5 - 10% lifetime risk [30]. Uncertainties in input parameters likely contributed to the wide range of future projections. Although we assumed that the average delay in diagnosis and treatment start would not change over the next ten years in our "status-quo" scenario, future NTP capacity expansion may reduce this delay and increase the case detection rate. Furthermore, our model implemented a synthetic social contact matrix from 2007, and an updated matrix would more accurately reflect current transmission dynamics, considering changes in social behavior, contact patterns, and demographics. While important, addressing drug-resistant (DR)-TB was beyond the scope of this study.

The major community-wide active case finding trial in Ca Mau province [32] provides opportunities for better understanding TB epidemiology in Vietnam and our modelling analysis can be considered in this context. The dramatic reduction in prevalence observed in ACT3 during the trial period may suggest that a larger proportion of cases result from early progression than late reactivation relative to our model estimates. However, we emphasize that our calibration process incorporated multiple epidemiological indicators, and our latency parameters - specifically early progression and late reactivation - were empirically derived, although all such estimates have their limitations. Additionally, we varied our latency parameters to some extent during calibration, and our supplementary materials indicate that early progression accounts for more than half of all cases in our model. While this discrepancy warrants further investigation, it highlights an important avenue for future research to refine our understanding of TB progression dynamics. Given the robustness of ACT3 as an epidemiological study, reconciling these differences could enhance the accuracy and applicability of our model to Viet Nam’s TB landscape.

Our study's strengths include our optimization and calibration approach, which harnessed state-of-the-art publicly available software tools and successfully captured key indicators of the epidemic while also reflecting uncertainty around key input parameters. The model was informed by multiple relevant data streams, including results from the recent TB national survey. This allowed us to replicate the local TB burden and ensure that historical trends in case detection were properly reflected through TB notification data. Our pipeline, which was also applied to COVID-19 [17], can simulate a broad range of directly transmitted pathogens, and so is particularly applicable to TB. Combining domain-specific syntax with other libraries from the data science ecosystem, our framework ensures accuracy, transparency, and efficiency while supporting detailed calibration and uncertainty analysis.

CONCLUSIONS

Our study underscores the significant impact of COVID-19-related disruptions on TB case detection in Vietnam, leading to a backlog of undiagnosed cases that could sustain transmission for years. However, these impacts may be mitigated by enhancing case detection activities, which can improve early detection and reduce transmission risks. Any major disruption now or into the future - whether due to another pandemic, other public health crises - could further exacerbate TB control challenges. Addressing these risks requires sustained investment in diagnostic capacity, healthcare system resilience, and proactive policies to mitigate the long-term consequences of such disruptions on TB control.

DECLARATIONS

Ethics approval and consent to participate: Not applicable, as this study involves modeling and does not include human participants or identifiable data.

Availability of data and materials: The data supporting this article and the code used for the analyses are accessible in a GitHub repository at: https://github.com/vlbui/tbdynamics.

Competing interests: The authors declare that they have no competing interests.

Author Contributions

Viet Long Bui: Conceptualization, Methodology, Software, Data Curation, Formal analysis, Writing- Original draft preparation; Writing- Reviewing and Editing; **Romain Ragonnet:** Conceptualization, Methodology, Software, Validation, Formal analysis, Writing- Reviewing and Editing; **Angus E. Hughes:** Methodology, Writing- Reviewing and Editing; **David S. Shipman:** Software; **Emma S. McBryde:** Writing- Reviewing and Editing; **Binh Hoa Nguyen :** Writing- Reviewing and Editing; **Hoang Nam Do:** Writing- Reviewing and Editing; **Thai Son Ha:** Writing- Reviewing and Editing; **Greg J. Fox:** Conceptualization, Data Curation, Methodology, Writing- Reviewing and Editing; **James M. Trauer:** Conceptualization, Methodology, Software, Validation, Formal analysis, Writing- Reviewing and Editing, Supervision.

Acknowledgements: Viet Long Bui is the recipient of a postgraduate scholarship from Monash University**.** James M. Trauer is the recipient of a Discovery Early Career Fellowship from the Australian Research Council (DE230100730). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. World Health Organization. Global Tuberculosis Report 2024. Geneva.

2. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022;10:603–22.

3. Villiers AK de, Osman M, Struchiner CJ, Trajman A, Tumu D, Shah VV, et al. Tuberculosis healthcare service disruptions during the COVID-19 pandemic in Brazil, India and South Africa: A model-based analysis of country-level data. PLOS Glob Public Health. 2025;5:e0003309.

4. Surendra H, Elyazar IRF, Puspaningrum E, Darmawan D, Pakasi TT, Lukitosari E, et al. Impact of the COVID-19 pandemic on tuberculosis control in Indonesia: a nationwide longitudinal analysis of programme data. Lancet Glob Health. 2023;11:e1412–21.

5. Hasan T, Nguyen VN, Nguyen HB, Nguyen TA, Le HTT, Pham CD, et al. Retrospective Cohort Study of Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020. Emerg Infect Dis. 2022;28:684–92.

6. World Health Organization. Global Tuberculosis Report 2021. Geneva.

7. Methods used by WHO to estimate the global burden of TB disease. https://www.who.int/publications/m/item/methods-used-by-who-to-estimate-the-global-burden-of-tb-disease-2022. Accessed 7 Feb 2025.

8. Ragonnet R, Williams BM, Largen A, Nasa J Jr, Jack T, Langinlur MK, et al. Estimating the long-term effects of mass screening for latent and active tuberculosis in the Marshall Islands. Int J Epidemiol. 2022;:dyac045.

9. Horby P, Thai PQ, Hens N, Yen NTT, Mai LQ, Thoang DD, et al. Social Contact Patterns in Vietnam and Implications for the Control of Infectious Diseases. PLOS ONE. 2011;6:e16965.

10. Completed results of the 2019 Viet Nam population and housing census – General Statistics Office of Vietnam. https://www.gso.gov.vn/en/data-and-statistics/2020/11/completed-results-of-the-2019-viet-nam-population-and-housing-census/. Accessed 30 May 2024.

11. TB profile. https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&iso2=%22AF%22&lan=%22EN%22. Accessed 30 May 2024.

12. Nguyen HV, Tiemersma EW, Nguyen HB, Cobelens FGJ, Finlay A, Glaziou P, et al. The second national tuberculosis prevalence survey in Vietnam. PLOS ONE. 2020;15:e0232142.

13. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat Comput. 2017;27:1413–32.

14. Summer documentation — Summer2 documentation. https://summer2.readthedocs.io/en/latest/. Accessed 4 Jun 2024.

15. Bennet P, Doerr C, Moreau A, Rapin J, Teytaud F, Teytaud O. Nevergrad: black-box optimization platform. SIGEVOlution. 2021;14:8–15.

16. DEMetropolis(Z) Sampler Tuning. PyMC. https://www.pymc.io/projects/examples/samplers/DEMetropolisZ_tune_drop_fraction.html. Accessed 6 Sep 2024.

17. Trauer JM, Hughes AE, Shipman DS, Meehan MT, Henderson AS, McBryde ES, et al. A Data Science Pipeline Applied to Australia's 2022 COVID-19 Omicron Waves. Infect Dis Model. 2024. https://doi.org/10.1016/j.idm.2024.08.005.

18. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88:273–80.

19. Ding C, Hu M, Guo W, Hu W, Li X, Wang S, et al. Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990–2019. Int J Infect Dis. 2022;122:46–62.

20. Kessel B, Heinsohn T, Ott JJ, Wolff J, Hassenstein MJ, Lange B. Impact of COVID-19 pandemic and anti-pandemic measures on tuberculosis, viral hepatitis, HIV/AIDS and malaria–A systematic review. PLOS Glob Public Health. 2023;3:e0001018.

21. Marco MH, Ahmedov S, Castro KG. The global impact of COVID-19 on tuberculosis: A thematic scoping review, 2020–2023. PLOS Glob Public Health. 2024;4:e0003043.

22. Innes AL, Lebrun V, Hoang GL, Martinez A, Dinh N, Nguyen TTH, et al. An Effective Health System Approach to End TB: Implementing the Double X Strategy in Vietnam. Glob Health Sci Pract. 2024;12:e2400024.

23. Dinh LV, Vo LNQ, Wiemers AMC, Nguyen HB, Vu HQ, Mo HTL, et al. Ensuring Continuity of Tuberculosis Care during Social Distancing through Integrated Active Case Finding at COVID-19 Vaccination Events in Vietnam: A Cohort Study. Trop Med Infect Dis. 2024;9:26.

24. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15.

25. Teo AKJ, Singh SR, Prem K, Hsu LY, Yi S. Duration and determinants of delayed tuberculosis diagnosis and treatment in high-burden countries: a mixed-methods systematic review and meta-analysis. Respir Res. 2021;22:251.

26. Stuck L, Klinkenberg E, Ali NA, Abukaraig EAB, Adusi-Poku Y, Wagaw ZA, et al. Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis. Lancet Infect Dis. 2024;24:726–36.

27. Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical Tuberculosis Disease—A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. Clin Infect Dis. 2021;73:e830–41.

28. Teo AKJ, MacLean EL-H, Fox GJ. Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics. Eur Respir Rev. 2024;33.

29. Assefa DG, Bedru A, Zeleke ED, Negash SE, Debela DT, Molla W, et al. Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials. Arch Public Health. 2023;81:82.

30. Dale KD, Karmakar M, Snow KJ, Menzies D, Trauer JM, Denholm JT. Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet Infect Dis. 2021;21:e303–17.

31. Mirzazadeh A, Kahn JG, Haddad MB, Hill AN, Marks SM, Readhead A, et al. State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. PloS One. 2021;16:e0249012.

32. Marks Guy B., Nguyen Nhung V., Nguyen Phuong T.B., Nguyen Thu-Anh, Nguyen Hoa B., Tran Khoa H., et al. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J Med. 2019;381:1347–57.